Skip to main content
. 2024 Feb 15;31(2):1047–1062. doi: 10.3390/curroncol31020078

Figure 4.

Figure 4

Proposed overview for the management of metastatic castration-resistant prostate cancer in the frontline setting. HRR: homologous recombination repair. * If not received previously; ** Notwithstanding access to rucaparib.